Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab

Journal of Neuro-Oncology

Volumn 121, Issue 2, 2015, Pages 373-380

  Kickingereder, Philipp ^a   Wiestler, Benedikt ^a,b   Graf, Markus ^b   Heiland, Sabine ^a   Schlemmer, Heinz Peter ^b   Wick, Wolfgang ^a,b   Wick, Antje ^a,b   Bendszus, Martin ^a   Radbruch, Alexander ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Bevacizumab; Dynamic contrast enhanced MRI; Glioblastoma; Volume transfer constant (Ktrans)

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; GADOTERATE MEGLUMINE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BLOOD VESSEL PARAMETERS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; IMAGE ANALYSIS; MALE; MICROVASCULAR PERMEABILITY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OVERALL SURVIVAL; PHARMACODYNAMICS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STEREOTACTIC BIOPSY; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84964239506     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1644-6     Document Type: Article

References (33)

1. Wong ET, Brem S (2008) Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. J Natl Compr Cancer Netw 6:515–522
2. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8:610–622. doi:10.1038/nrn2175/nrn2175
3. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972
4. Leu K, Pope WB, Cloughesy TF, Lai A, Nghiemphu PL, Chen W, Liau LM, Ellingson BM (2013) Imaging biomarkers for antiangiogenic therapy in malignant gliomas. CNS Oncol 2:33–47. doi:10.2217/cns.12.29
5. O’Connor JP, Jayson GC (2012) Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors? Clin Cancer Res 18:6588–6598. doi:10.1158/1078-0432.CCR-12-1501
6. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ (2013) Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 31:1219–1230. doi:10.1200/JCO.2012.46.2762
7. Tofts PS (2010) T1-weighted DCE imaging concepts: modelling, acquisition and analysis. MAGNETOM Flash 3:30–39
8. Cha S (2006) Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol 27:475–487
9. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95. doi:10.1016/j.ccr.2006.11.021
10. Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK (2009) A “vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69:5296–5300. doi:10.1158/0008-5472.CAN-09-0814
11. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223–232
12. Mouridsen K, Christensen S, Gyldensted L, Ostergaard L (2006) Automatic selection of arterial input function using cluster analysis. Magn Reson Med 55:524–531. doi:10.1002/mrm.20759
13. Murase K (2004) Efficient method for calculating kinetic parameters using T1-weighted dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Med 51:858–862. doi:10.1002/mrm.20022
14. Galban CJ, Chenevert TL, Meyer CR, Tsien C, Lawrence TS, Hamstra DA, Junck L, Sundgren PC, Johnson TD, Ross DJ, Rehemtulla A, Ross BD (2009) The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 15:572–576. doi:10.1038/nm.1919
15. Flaherty KT, Rosen MA, Heitjan DF, Gallagher ML, Schwartz B, Schnall MD, O’Dwyer PJ (2008) Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 7:496–501
16. Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ, Stadler WM (2008) Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 26:4572–4578. doi:10.1200/JCO.2007.15.5655
17. Hsu CY, Shen YC, Yu CW, Hsu C, Hu FC, Hsu CH, Chen BB, Wei SY, Cheng AL, Shih TT (2011) Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. J Hepatol 55:858–865. doi:10.1016/j.jhep.2011.01.032
18. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27:3027–3035. doi:10.1200/JCO.2008.20.9908
19. Bjarnson GA, Williams R, Hudson JM, Bailey C, Lee CR, Lloyd BA, Kandel S, Ebos JM, Kiss A, Kerbel RS, Milot LM, Atri M, Stanisz GJ, Burns P (2011) Microbubble ultrasound (DCE-US) compared to DCE-MRI and DCE-CT for the assessment of vascular response to sunitinib in renal cell carcinoma (RCC). J Clin Oncol 29:4627
20. Zhang W, Kreisl T, Solomon J, Reynolds R, Glen D, Cox R, Fine H, Butman J (2009) Acute effects of bevacizumab on glioblastoma vascularity assessed with DCE-MRI and relation to patient survival. Proc Intl Soc Magn Reson Med 17:282
21. Verhoeff JJ, Lavini C, van Linde ME, Stalpers LJ, Majoie CB, Reijneveld JC, van Furth WR, Richel DJ (2010) Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol 21:1723–1727. doi:10.1093/annonc/mdp591
22. Cha S, Yang L, Johnson G, Lai A, Chen MH, Tihan T, Wendland M, Dillon WP (2006) Comparison of microvascular permeability measurements, K(trans), determined with conventional steady-state T1-weighted and first-pass T2*-weighted MR imaging methods in gliomas and meningiomas. AJNR Am J Neuroradiol 27:409–417
23. Nguyen TB, Cron GO, Mercier JF, Foottit C, Torres CH, Chakraborty S, Woulfe J, Jansen GH, Caudrelier JM, Sinclair J, Hogan MJ, Thornhill RE, Cameron IG (2012) Diagnostic accuracy of dynamic contrast-enhanced MR imaging using a phase-derived vascular input function in the preoperative grading of gliomas. AJNR Am J Neuroradiol 33:1539–1545. doi:10.3174/ajnr.A3012
24. Patankar TF, Haroon HA, Mills SJ, Baleriaux D, Buckley DL, Parker GJ, Jackson A (2005) Is volume transfer coefficient (K(trans)) related to histologic grade in human gliomas? AJNR Am J Neuroradiol 26:2455–2465
25. Zhou YH, Tan F, Hess KR, Yung WK (2003) The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res 9:3369–3375
26. Abdulrauf SI, Edvardsen K, Ho KL, Yang XY, Rock JP, Rosenblum ML (1998) Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg 88:513–520. doi:10.3171/jns.1998.88.3.0513
27. Carlson MR, Pope WB, Horvath S, Braunstein JG, Nghiemphu P, Tso CL, Mellinghoff I, Lai A, Liau LM, Mischel PS, Dong J, Nelson SF, Cloughesy TF (2007) Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res 13:2592–2598. doi:10.1158/1078-0432.CCR-06-2772
28. Kickingereder P, Sahm F, Wiestler B, Roethke M, Heiland S, Schlemmer HP, Wick W, von Deimling A, Bendszus M, Radbruch A (2014) Evaluation of microvascular permeability with dynamic contrast-enhanced mri for the differentiation of primary cns lymphoma and glioblastoma: radiologic-pathologic correlation. AJNR Am J Neuroradiol. doi:10.3174/ajnr.A3915
29. Guo JY, Reddick WE, Rosen MA, Song HK (2009) Dynamic contrast-enhanced magnetic resonance imaging parameters independent of baseline T10 values. Magn Reson Imaging 27:1208–1215. doi:10.1016/j.mri.2009.05.015
30. Jung SC, Yeom JA, Kim JH, Ryoo I, Kim SC, Shin H, Lee AL, Yun TJ, Park CK, Sohn CH, Park SH, Choi SH (2014) Glioma: application of histogram analysis of pharmacokinetic parameters from T1-weighted dynamic contrast-enhanced MR imaging to tumor grading. AJNR Am J Neuroradiol 35:1103–1110. doi:10.3174/ajnr.A3825
31. Heisen M, Fan X, Buurman J, van Riel NA, Karczmar GS, ter Haar Romeny BM (2010) The influence of temporal resolution in determining pharmacokinetic parameters from DCE-MRI data. Magn Reson Med 63:811–816. doi:10.1002/mrm.22171
32. Henderson E, Rutt BK, Lee TY (1998) Temporal sampling requirements for the tracer kinetics modeling of breast disease. Magn Reson Imaging 16:1057–1073
33. Bagher-Ebadian H, Jain R, Nejad-Davarani SP, Mikkelsen T, Lu M, Jiang Q, Scarpace L, Arbab AS, Narang J, Soltanian-Zadeh H, Paudyal R, Ewing JR (2012) Model selection for DCE-T1 studies in glioblastoma. Magn Reson Med 68:241–251. doi:10.1002/mrm.23211